Similar articles

• Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.

  Lipton A, Ali SM, Leitzel K, Demers L, Harvey HA, Chaudri-Ross HA, Brady C, Wyld P, Carney W. Lipton A, et al. J Clin Oncol. 2003 May 15;21(10):1967-72. doi: 10.1200/JCO.2003.09.098. J Clin Oncol. 2003. PMID: 12743150 Clinical Trial.
• Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.

  Lipton A, Leitzel K, Ali SM, Demers L, Harvey HA, Chaudri-Ross HA, Evans D, Lang R, Hackl W, Hamer P, Carney W. Lipton A, et al. Cancer. 2005 Jul 15;104(2):257-63. doi: 10.1002/cncr.21202. Cancer. 2005. PMID: 15952182
• [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].

  Illiger HJ. Illiger HJ. Strahlenther Onkol. 2002 Feb;178(2):111-3. Strahlenther Onkol. 2002. PMID: 11942036 Clinical Trial. German. No abstract available.
• Understanding the BIG results: Insights from the BIG 1-98 trial analyses.

  Wardley AM. Wardley AM. Adv Ther. 2008 Dec;25(12):1257-75. doi: 10.1007/s12325-008-0128-5. Adv Ther. 2008. PMID: 19096768 Review.
• Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?

  Kaufmann M, Rody A. Kaufmann M, et al. Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):146-54. doi: 10.1016/j.ejogrb.2006.03.006. Epub 2006 Apr 18. Eur J Obstet Gynecol Reprod Biol. 2006. PMID: 16621229 Review.